Der er vist mye mere
Session 14:
PCI and Other Drug Delivery Methods
Monday 1 July 2019
2:00 PM - 3:45 PM
Location: Concept
Session Chairs:
Per Walday, PCI Biotech AS (Norway) ;
Mans Broekgaarden, Institut pour l’Avancée des Biosciences (France)
This session is sponsored in part by:

The scientific basis of photochemical internalization (PCI) (Invited Paper)
Paper 11070-92
Time: 2:00 PM - 2:20 PM
Author(s): Kristian Berg, Oslo Univ. Hospital (Norway)
Hide Abstract
Add To My Schedule 
Some photosensitizers (PSs) have been found to localize in lysosomes and endosomes. Such vesicles are ruptured upon exposure of the cells to light and the PS relocated to other compartments in the cells. This rupture is expected to cause cytotoxicity. However, it was found that a large fraction of the vesicles containing PSs could be ruptured without inducing substantial cytotoxicity. The scientific basis for this surprising observation as well as the potential utilization of the photochemical rupture of endosomes and lysosomes for intracellular delivery of various therapeutics, named photochemical internalization (PCI), will be discussed.
Review of photochemical internalisation (PCI) applications (Invited Paper)
Paper 11070-93
Time: 2:20 PM - 2:40 PM
Author(s): Anders Høgset, Per Walday, PCI Biotech AS (Norway)
Hide Abstract
Add To My Schedule 
Photochemical internalization (PCI) can be used for enhancing intracellular delivery of many different types of molecules with therapeutic activity or therapeutic potential. Thus, in preclinical studies promising effects have been demonstrated with small molecule anticancer therapeutics and antibiotics, as well as a variety of macromolecules, such as protein and peptide antigens, protein toxins and immunotoxins, various nucleic acids and nanoparticles. Different application areas of the PCI technology will be discussed with the focus on the use with small molecules, in vaccination, and for enhancing delivery of nucleic acids. Other potential uses of PCI will also be briefly discussed.
Photochemical internalization: current clinical trials in cholangiocarcinoma (Invited Paper)
Paper 11070-94
Time: 2:40 PM - 3:00 PM
Author(s): Hans Olivecrona, PCI Biotech AS (Norway)
Hide Abstract
Add To My Schedule 
Cholangiocarcinoma (CCA) is a rare cancer, most commonly located extrahepatic. Gemcitabine/cisplatin standard treatment results in a median PFS of 8 and OS of 12 months. PCI is well suited for CCA; gemcitabine effects are enhanced and PCI applicable endoscopically. A phase I dose escalation trial of PCI with gemcitabiine preceding standard gem/cis treatment resulted in a median OS of 21.7 months in the highest dose, without major safety concerns. With these encouraging data, and improved local therapy needs, the RELEASE study, a pivotal 1:1 randomized trial comparing SoC chemotherapy +/- PCI in Europe and the United States is now initiated.